Medically reviewed by ChinaCureLink Team
Table of Content
Introduction
When you are told that stomach cancer has returned, one of the first questions is usually, "What can we do now?" That question becomes even harder when you have already gone through surgery, chemotherapy, radiation or immunotherapy.
The important thing to understand is that recurring stomach cancer does not automatically mean there are no options left. It also does not mean that the treatment that worked the first time should simply be repeated. Doctors need to look at where the cancer has returned, what treatments you have already received and what the cancer's biology tells them about the next step.
For families considering treatment overseas, another question is becoming increasingly relevant: Could a treatment or clinical trial available in China be appropriate for this particular cancer?
Key Takeaways |
|
What Should Happen First When Stomach Cancer Comes Back?
Before choosing another treatment, doctors generally need to establish exactly what has happened.
The cancer may have returned near the original tumor, in lymph nodes or at distant sites. Imaging, biopsy and other investigations can help determine the extent of recurrence.
For advanced or recurrent gastric cancer, biomarker testing is also important. The National Cancer Institute identifies HER2, mismatch-repair deficiency (dMMR)/microsatellite instability (MSI), and PD-L1 as important testing considerations in metastatic gastric adenocarcinoma.
CLDN18.2 testing has also become particularly relevant as newer targeted therapies and CAR-T approaches have emerged.
If you are seeking another opinion, gather your pathology reports, biopsy results, imaging, treatment history and biomarker results before making major decisions.
What are the Standard Treatment Options for Recurrent Stomach Cancer?
There is no single "best treatment" for every patient.
Depending on the circumstances, treatment can include chemotherapy, immunotherapy, targeted therapy, radiation, surgery in selected cases, clinical trials and palliative treatments to control symptoms.
Chemotherapy remains an important treatment for many patients with advanced or recurrent gastric cancer. However, the choice of drugs depends on what has already been used and how the cancer responded.
Immunotherapy may be appropriate for selected patients, particularly when tumor characteristics such as PD-L1 expression or MSI-H/dMMR status support its use.
Targeted therapy may also be considered when the tumor carries a relevant biomarker. For example, HER2-positive gastric cancer can be treated with HER2-directed therapies in appropriate settings.
This is why a second opinion can sometimes be useful after recurrence: the diagnosis alone does not tell the whole story.
Why is CLDN18.2 Testing Becoming Important?
CLDN18.2 is a protein that can be found at high levels in some gastric and gastroesophageal junction cancers. It has become an important target for drug development.
For example, the FDA approved zolbetuximab in 2024, in combination with chemotherapy, for adults with CLDN18.2-positive, HER2-negative locally advanced unresectable or metastatic gastric or GEJ adenocarcinoma in the first-line setting.
CLDN18.2 is also the target of satri-cel, a CAR-T therapy that has changed the discussion around advanced gastric cancer.
That makes a practical question worth asking your oncology team:
Has my tumor been tested for CLDN18.2?
If it has not, ask whether testing of existing tissue or a new biopsy is appropriate.
Could CAR-T Therapy Be an Option for Recurring Stomach Cancer?
For a specific group of patients, yes.
In June 2026, China's National Medical Products Administration approved satricabtagene autoleucel (satri-cel, CT041) for patients with CLDN18.2-positive, HER2-negative advanced gastric or gastroesophageal junction adenocarcinoma who have failed at least two prior lines of therapy. It became the first CAR-T therapy approved for a solid tumor.
The approval followed clinical research conducted in China.
In the final Phase 1 study published in Nature Medicine in 2024, 98 patients with CLDN18.2-positive advanced gastrointestinal cancers received satri-cel. The overall response rate was 38.8%, disease control rate was 91.8%, median progression-free survival was 4.4 months, and median overall survival was 8.8 months.
The randomized Phase 2 CT041-ST-01 trial provided stronger comparative evidence. It enrolled 156 patients with previously treated, CLDN18.2-positive advanced gastric or GEJ cancer. Median progression-free survival was 3.25 months with satri-cel versus 1.77 months with physician's-choice treatment, while the confirmed response rate was 22% versus 4%.
These results are encouraging, but they should be interpreted in context. The patients were selected based on specific eligibility criteria and had advanced disease after previous treatments. CAR-T is not appropriate for every person whose stomach cancer has returned.
What are the Risks of CAR-T?
CAR-T is a complex treatment and requires close medical monitoring.
In the Phase 1 study, cytokine release syndrome occurred in 96.9% of patients, although all reported cases were grade 1–2. Gastric mucosal injuries occurred in 8.2%, and no treatment-related deaths or immune effector cell-associated neurotoxicity syndrome (ICANS) were reported in that study.
Patients therefore need to discuss both potential benefits and risks with a qualified cellular-therapy team.
Is China Still Conducting Clinical Trials for Stomach Cancer?
Yes. China's role in this field extends beyond the satri-cel approval.
Chinese research centers continue to investigate CAR-T and other CLDN18.2-directed approaches, including strategies intended to move treatment earlier in the course of gastric cancer.
For example, ongoing research has included sequential treatment after first-line therapy and consolidation approaches following surgery or adjuvant treatment.
A small 2026 subgroup report involving five patients investigated satri-cel as sequential therapy after first-line treatment. Among four patients with measurable target lesions, all responded. Two later underwent surgery and were reported alive beyond 51 and 58 months. These findings are interesting, but because the group contained only five patients, they should be regarded as exploratory rather than typical expected outcomes.
Other Chinese programs are also investigating next-generation cellular therapies and additional CLDN18.2-targeted strategies.
For patients, this creates an important distinction:
An approved treatment is not the same thing as a clinical trial.
A clinical trial may provide access to an investigational treatment that is not yet routinely available, but eligibility is determined by the individual study. The trial may require a particular biomarker, treatment history, disease location, performance status or other criteria.
What if Treatment Options at Home are Becoming Limited?
This is often when international treatment becomes worth investigating.
You may have been told that standard treatments are no longer working, a particular therapy is unavailable or a clinical trial is not accessible in your country.
Travelling to China does not automatically solve those problems. The first question should be whether there is a medically appropriate treatment pathway for your individual case.
For someone considering satri-cel, for example, the key factors include the cancer diagnosis, CLDN18.2 status, HER2 status and previous treatment lines.
That is why a remote medical-record review can be useful before booking flights.
How ChinaCureLink Can Help International Patients with Recurring Stomach Cancer
ChinaCureLink helps international patients organize their medical records and explore appropriate treatment pathways at Chinese hospitals.
For recurring stomach cancer, this can include:
Medical-record review: Pathology, imaging, biomarker results and previous treatment records are organized for specialist assessment.
Hospital matching: The goal is to identify a hospital and oncology team with relevant expertise rather than simply selecting a hospital because it offers a particular treatment.
Eligibility assessment: If CAR-T or a clinical trial is being considered, the treating team determines whether the patient meets the relevant medical criteria.
International coordination: If the hospital accepts the patient, ChinaCureLink can assist with communication, documentation, travel planning and treatment logistics.
The important point is that ChinaCureLink does not decide whether a treatment is medically appropriate. That decision belongs to the qualified treating physicians after reviewing the patient's complete medical information.
Get a Second Opinion Before Fly to China
For suitable cases, ChinaCureLink can then coordinate an online consultation with the specialist to discuss the technical treatment details directly. The purpose is to help the patient understand which treatment option and which specialist center may be most appropriate before making an international treatment decision.
What Patients Say About ChinaCureLink & Medebound HEALTH
China CureLink operates under Medebound HEALTH — an internationally recognized healthcare navigation company incorporated in New York, with operations across North America and Asia-Pacific.
Rated 4.6 ⭐⭐⭐⭐⭐ at Trustpilot
Medebound HEALTH's online testimonials. Learn More
Frequently Asked Questions
What is the Best Treatment for Recurring Stomach Cancer?
There is no single best treatment for everyone. Options may include chemotherapy, immunotherapy, targeted therapy, radiation, surgery in selected cases, clinical trials and CAR-T for a specific group of CLDN18.2-positive patients. Treatment depends on recurrence, biomarkers, previous therapies and overall health.
Should Recurrent Stomach Cancer be Tested for CLDN18.2?
CLDN18.2 testing can be important because it may identify eligibility for certain targeted treatments and CAR-T approaches. It should be discussed with the treating oncology team, particularly when standard treatment options are becoming limited.
Is CAR-T Approved for Stomach Cancer in China?
Yes. China approved satri-cel in June 2026 for CLDN18.2-positive, HER2-negative advanced gastric/GEJ adenocarcinoma after at least two prior lines of therapy. It is a specific indication, not a treatment for all recurrent stomach cancers.
Is China Still Running Gastric Cancer CAR-T Trials?
Yes. Chinese research programs continue to investigate CLDN18.2-directed CAR-T approaches, including sequential and earlier-line strategies. Trial availability and eligibility change over time, so patients need to confirm that a study is actively recruiting and that they meet its criteria.
Can International Patients Seek Gastric Cancer Treatment in China?
International patients can explore treatment through Chinese hospitals, but acceptance depends on the diagnosis, biomarker profile, previous treatment and hospital-specific requirements. A remote case review before travel can help establish whether a particular treatment pathway is worth pursuing.
About ChinaCureLink
ChinaCureLink helps patients across the world access the best cancer treatment at China's top hospitals, without the delays, language barriers, and administrative confusion that typically come with seeking care abroad.
We connect patients directly with China's top cancer hospitals, ensuring that from the first case submission through to treatment and follow-up, every step is guided, translated, and coordinated by a team experienced in cross-border patient care.
ChinaCureLink is proudly affiliated with Medebound HEALTH — founded by US physicians, with over 10 years of experience and more than 3,000 patients served worldwide, Medebound HEALTH is recognized by Forbes and it is one of the most trusted patient cross-border concierge service company across North America and the Asia Pacific.
Disclaimer
This article is for informational purposes only and is not medical or financial advice. Treatment eligibility, protocols, and costs vary by individual case — confirm specifics with a coordinator and treating physician before making any decisions.
References
National Cancer Institute — Gastric Cancer Treatment (PDQ®). NCI Gastric Cancer Treatment
Qi C, et al. Claudin18.2-specific CAR T cells in gastrointestinal cancers: phase 1 trial final results. Nature Medicine, 2024. Nature Medicine study
Qi C, et al. Satricabtagene autoleucel versus treatment of physician's choice for previously treated advanced gastric or gastro-oesophageal junction cancer. The Lancet, 2025. Lancet study
CARsgen Therapeutics — 2026 satri-cel approval announcement. Approval announcement
ASCO — Long-term follow-up of satri-cel as sequential therapy after first-line treatment for advanced gastric cancer. ASCO report
ChinaCureLink — Gastric Cancer CAR-T in China: The Complete 2026 Access Guide for International Patients. ChinaCureLink CAR-T Guide